SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes

Sponsor

Sarcoma Alliance for Research through Collaboration (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT02048371

Collaborator

(none)

150

Enrollment

Locations

Arms

Anticipated Duration (Months)

8.3

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Although regorafenib was approved for use in patients who had progressive GIST despite imatinib and/or sunitinib on the basis of phase II and phase III data, it has not been examined in a systematic fashion in patients with other forms of sarcoma.

Given the activity of sorafenib, sunitinib and pazopanib in soft tissue sarcomas, and evidence of activity of sorafenib in osteogenic sarcoma and possibly Ewing/Ewing-like sarcoma, there is precedent to examine SMOKIs (small molecule oral kinase inhibitors) such as regorafenib in sarcomas other than GIST. It is also recognized that SMOKIs (small molecule oral kinase inhibitors)such as regorafenib, sorafenib, pazopanib, and sunitinib have overlapping panels of kinases that are inhibited simultaneously. While not equivalent, most of these SMOKIs (small molecule oral kinase inhibitors) block vascular endothelial growth factor and platelet derived growth factors receptors (VEGFRs and PDGFRs), speaking to a common mechanism of action of several of these agents.

Condition or Disease	Intervention/Treatment	Phase
Liposarcoma Osteogenic Sarcoma Ewing/Ewing-like Sarcoma Rhabdomyosarcoma Mesenchymal Chondrosarcoma	Drug: Regorafenib Drug: Placebo	Phase 2

Detailed Description

Study Design

Study Type:

Interventional

Anticipated Enrollment :

150 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

Triple (Participant, Care Provider, Investigator)

Primary Purpose:

Treatment

Official Title:

SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes

Actual Study Start Date :

Jul 1, 2014

Anticipated Primary Completion Date :

May 1, 2022

Anticipated Study Completion Date :

Jun 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Cohort A: Liposarcoma Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib	Drug: Regorafenib Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
Placebo Comparator: Cohort A: Liposarcoma, Placebo 21 days on and 7 days off Placebo	Drug: Placebo 21 days on and 7 days off
Active Comparator: Cohort B: Osteosarcoma Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib	Drug: Regorafenib Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
Placebo Comparator: Cohort B: Osteosarcoma, placebo 21 days on and 7 days off Placebo	Drug: Placebo 21 days on and 7 days off
Active Comparator: Cohort C: Ewing sarcoma Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib	Drug: Regorafenib Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
Active Comparator: Cohort D: Rhabdomyosarcoma Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib	Drug: Regorafenib Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
Active Comparator: Cohort E: Mesenchymal Chondrosarcoma Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib	Drug: Regorafenib Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off

Outcome Measures

Primary Outcome Measures

Progression-free survival (PFS). Cohort A [up to 3 years]
The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. Cohort A (liposarcoma). PFS will be evaluated according to RECIST (Response Evaluation Criteria In Solid Tumors) 1.1.
Progression-free survival (PFS). Cohort B [up to 3 years]
The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. Cohort B (osteogenic sarcoma). PFS will be evaluated according to RECIST (Response Evaluation Criteria In Solid Tumors) 1.1.
Progression-free survival (PFS). Cohort C [up to 16 weeks]
The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. Cohort C (Ewing/Ewing-like sarcoma). PFS will be evaluated according to RECIST (Response Evaluation Criteria In Solid Tumors) 1.1.
Progression-free survival (PFS). Cohort D [up to 16 weeks]
The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. Cohort D (Rhabdomyosarcoma). PFS will be evaluated according to RECIST (Response Evaluation Criteria In Solid Tumors) 1.1.
Progression-free survival (PFS). Cohort E [up to 16 weeks]
The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. Cohort E (Mesenchymal Chondrosarcoma). PFS will be evaluated according to RECIST (Response Evaluation Criteria In Solid Tumors) 1.1.

Secondary Outcome Measures

The incidence of reported CTCAE (Common Terminology Criteria for Adverse Events) version 4.03 adverse events. All cohorts. [up to 3 years]
Common Toxicity Criteria, also referred to as the Common Terminology Criteria for Adverse Events (CTCAE), is a standardised classification of side effects used in assessing drugs for cancer therapy. Cohorts A, B, C, and D.
Overall response rate (ORR). All cohorts. [up to 3 years]
The overall response rate (ORR) is the percentage of patients whose cancer shrinks or disappears after treatment. ORR will be evaluated according to RECIST (Response Evaluation Criteria In Solid Tumors) 1.1
Progression-free survival (PFS), Cohorts A and B, after crossover. [up to 3 years]
The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.
Response rate (RR), Cohorts A and B, after crossover. [up to 3 years]
The response rate (RR) is the percentage of patients whose cancer shrinks or disappears after treatment.
Time to tumor progression (TTP), Cohorts A and B, after crossover. [up to 3 years]
Time to tumor progression (TTP) is the length of time from the date of diagnosis or the start of treatment for a disease until the disease starts to get worse or spread to other parts of the body.
overall survival (OS). Cohorts A and B, after crossover. [up to 3 years]
Overall survival (OS) is the length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.
Disease Specific Survival (DSS). Cohorts A and B, after crossover. [up to 3 years]
Disease-specific survival refers to the percentage of people in a study or treatment group who have not died from a specific disease in a defined period of time.

Eligibility Criteria

Criteria

Ages Eligible for Study:

5 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age ≥ 10 year for Liposarcoma, Osteosarcoma, Ewing sarcoma and Mesenchymal Chondrosarcoma; Age ≥ 5 years for Rhabdomyosarcoma cohorts
Weight ≥ 15 kg (33 lb)
Patients must have histologically or cytologically confirmed advanced/metastatic liposarcoma, osteogenic sarcoma, Ewing/Ewing-like sarcoma of soft tissue or bone, fusion-positive alveolar rhabdomyosarcoma or embryonal rhabdomyosarcoma/fusion-negative alveolar rhabdomyosarcoma , or mesenchymal chondrosarcoma
WHO Performance Status 0, 1 or 2. A maximum of 1/3 of patients in cohorts A & B may be WHO performance status 2
At least one prior line of systemic therapy for the sarcoma diagnosis (neoadjuvant, adjuvant or metastatic disease)
All acute toxic effects of any prior treatment have resolved to NCI-CTCAE v 4.0 Grade 1 or less (except alopecia) at the time of signing the Informed Consent Form (ICF)
Subject must be able to swallow and retain oral medication
At least one site of measurable disease on x-ray/CT/MRI scan as defined by RECIST 1.1
Adequate organ function within 14 days of registration
Written, voluntary informed consent
Fertile men and women of childbearing potential must agree to use an effective method of birth control from Day 1 of study and for 3 months after last study drug administration in both sexes, as assessed by the investigator. Women of childbearing potential include pre-menopausal women and women within the first 2 years of the onset of menopause. Women of childbearing potential must have a negative pregnancy test less than or equal to seven days prior to Day 1 of study. The definition of adequate contraception will be based on the judgement of the investigator.
Evidence of progression of disease as defined by RECIST 1.1 (i.e. new disease sites or 20% growth of index lesions) within 6 months of registration
Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS (central nervous system) metastatic disease and are without evidence of clinical progression for at least 12 weeks after therapy

Exclusion Criteria:

Patients with documentation of well differentiated liposarcoma only (of the well differentiated/dedifferentiated liposarcoma family) are specifically excluded, owing to its characteristically slow growth. If high grade areas are suspected (dedifferentiation), but not proved by pathology analysis (e.g. after primary resection of a well-differentiated liposarcoma), a biopsy must be performed to demonstrate the high-grade dedifferentiated disease
Prior systemic therapy with a small molecule oral kinase inhibitor, including but not limited to: pazopanib, sunitinib, sorafenib, everolimus, sirolimus, vemurafenib, dasatinib and trametinib
Previous assignment to treatment during this study. Subjects permanently withdrawn from study participation will not be allowed to re-enter study. Patients who progress on placebo are specifically allowed to enroll on the treatment arm of the study if they meet all other entry criteria
Concurrent, clinically significant, active malignancies within 12 months of study enrollment
Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol
Major surgery within 28 days prior to study registration or those patients who have not recovered adequately from prior surgery
Patients who have received wide field radiotherapy ≤ 28 days (defined as > 50% of volume of pelvis bones or equivalent) or limited field radiation for palliation < 14 days prior to study registration or those patients who have not recovered adequately from side effects of such therapy
Patients who have received prior systemic therapy < 14 days prior to study registration or have not recovered adequately from toxicities to CTCAE v. 4.03 grade 1 or less; prior investigational therapy may not have been given < 5 half-lives of last dose of treatment, or < 14 days, whichever is greater
Patients who have had prior autologous, or allogeneic bone marrow transplant
Uncontrolled hypertension (systolic pressure >140 mm Hg or diastolic pressure > 90 mm Hg [NCI-CTCAE v 4.0] on repeated measurement) despite optimal medical management
Active or clinically significant cardiac disease including: Congestive heart failure-New York Heart Association (NYHA) > class II, Active coronary artery disease, Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, Unstable angina (anginal symptoms at rest), new onset angina within 3 months before randomization, or myocardial infarction within 6 months before randomization
Evidence or history of bleeding diathesis
Any hemorrhage or bleeding event ≥ NCI CTCAE Grade 3 within 4 weeks prior to study registration
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatment
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy.
Ongoing infection > Grade 2 NCI-CTCAE v 4.03
Presence of a non-healing wound, non-healing ulcer, or benign bone fracture (patients with stress insufficiency fractures e.g. from osteoporosis or pathological fracture from tumor are eligible for study)
Patients with seizure disorder requiring medication
Proteinuria > 100 mg/dl on urine analysis
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Pleural effusion or ascites that causes respiratory compromise (≥ NCI-CTCAE version 4.03 Grade 2 dyspnea)
History of organ allograft (including corneal transplant).
Known or suspected allergy or hypersensitivity to regorafenib, or excipients of the formulations given during the course of this trial
Any malabsorption condition.
Women who are pregnant or breast-feeding.
Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation
Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results
Inability to comply with protocol required procedures
Use of any herbal remedy (e.g. St. John wort [Hypericum perforatum])

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	City of Hope National Medical Center	Duarte	California	United States	91010
2	Children's Hospital Los Angeles	Los Angeles	California	United States	90027
3	Sarcoma Oncology Research Center	Santa Monica	California	United States	90403
4	Stanford University	Stanford	California	United States	94305
5	Mayo Clinic - Florida	Jacksonville	Florida	United States	32224
6	H. Lee Moffitt	Tampa	Florida	United States	33612
7	Northwestern University	Chicago	Illinois	United States	60611
8	Indiana University	Indianapolis	Indiana	United States	46202
9	Dana Farber/Partners Cancer Care	Boston	Massachusetts	United States	02215
10	Mayo Clinic - Minnesota	Rochester	Minnesota	United States	55905
11	Carolinas Healthcare System	Charlotte	North Carolina	United States	28203
12	Duke University	Durham	North Carolina	United States	27705
13	Ohio State University	Columbus	Ohio	United States	43202
14	Oregon Health and Science University	Portland	Oregon	United States	97239
15	Vanderbilt University	Nashville	Tennessee	United States	37232
16	Texas Children's Hospital	Houston	Texas	United States	77030
17	Huntsman Cancer Institute	Salt Lake City	Utah	United States	84112
18	Seattle Cancer Care Alliance	Seattle	Washington	United States	98109